<DOC>
	<DOCNO>NCT01297920</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy new ophthalmic suspension ( Brinz/Brim ) lower intraocular pressure ( IOP ) relative individual active component subject open-angle glaucoma and/or ocular hypertension .</brief_summary>
	<brief_title>Three Month Efficacy/Safety Study With 3-Month Safety Extension Brinzolamide 1 % /Brimonidine 0.2 % vs. Brinzolamide 1 % Brimonidine 0.2 %</brief_title>
	<detailed_description>This study consist 7 visit conduct 2 sequential phase : screening/eligibility phase , include screen visit 2 eligibility visit , treatment phase , include 4 on-therapy visit conduct Week 2 , Week 6 , Month 3 , Month 6 . A washout period base previous ocular medication precede Eligibility Visit 1 . Subjects meet inclusion/exclusion criterion eligibility visit randomize 1 3 study drug group . The study design evaluate efficacy safety Brinzolamide/Brimonidine 3-month period , additional 3 month study drug exposure intend provide safety data .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Sign Informed Consent document . Diagnosis openangle glaucoma ocular hypertension , mean intraocular pressure within protocolspecified range eligibility visit/s . Other protocolspecified inclusion criterion may apply . Females childbearing potential pregnant , lactating , use highly effective birth control measure . Any form glaucoma openangle glaucoma . Severe central vision loss either eye . Chronic , recurrent , severe inflammatory eye disease . Ocular trauma within precede 6 month . Ocular infection ocular inflammation within precede 3 month . Clinically significant progressive retinal disease retinal degeneration , diabetic retinopathy , retinal detachment . Bestcorrected visual acuity score worse 55 letter use Early Treatment Diabetic Retinopathy Study chart . Other ocular pathology ( include severe dry eye ) may , opinion Investigator , preclude administration study product . Ocular surgery within precede 6 month . Ocular laser surgery within precede 3 month . Any abnormality prevent reliable applanation tonometry . Any condition , include severe illness , could make subject , opinion Investigator , unsuitable study . Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
	<keyword>Brinzolamide</keyword>
	<keyword>Brimonidine</keyword>
	<keyword>Intraocular pressure</keyword>
</DOC>